"In 1980, the number of people with diabetes in the world was 108 million; in 2014, the number of patients was increased to 422 million. Diabetes has surged 314 million people over the past 35 years, with an average annual growth of nearly 9 million." WHO released data at the beginning of the year. It is estimated that 1 million 500 thousand people will die of diabetes worldwide in 2012, and 2 million 200 thousand people will die from diabetes complications.
Diabetes is a very serious chronic disease in which the pancreas fails to produce enough insulin or the pancreas does not properly use the insulin it produces. Diabetes itself is not terrible, terrible is that it brings complications, patients may lead to myocardial infarction, stroke, blindness, kidney failure and amputation and other serious consequences. Admittedly, diabetes has become one of the major killers of current human health.
At present, the key to treating diabetes is insulin, the hormone that was discovered in 1921, is the human body to control glucose or glucose, are unable to produce enough insulin in the body affect human health, exogenous insulin came into being. The development of insulin has undergone three stages: animal insulin, gene recombinant human insulin, and insulin analog. At present, insulin analogues occupy the insulin market with absolute predominance.
Insulin position dominant market stabilization
According to IMS database statistics, in 2015 the global diabetes market size of nearly 58 billion 300 million U. s.dollars, an increase of 15.1%, great prospects. There are three types of diabetes drugs in the market today: insulin, GLP-1 receptor agonists and oral small molecules. In the three categories of drugs for the treatment of diabetes, insulin drug market share accounted for most, the two or three generation of insulin has the absolute market dominance, imitation, inhaled insulin in 2015 finally broke the 0 history made some achievements, but the proportion is very little. Overall, in recent years the diabetes market stabilization of insulin drug sales.